Patent Application: Bifidobacterium longum for Infant Infection Prevention
Summary
The USPTO has published a patent application (US20260083785A1) detailing the use of Bifidobacterium longum transitional microorganisms to prevent or reduce the risk of infection in infants and young children. The application was filed on September 27, 2023.
What changed
This document is a published patent application from the USPTO, specifically application US20260083785A1, filed on September 27, 2023. It describes the use of a Bifidobacterium longum transitional microorganism for preventing or reducing the risk of infection in infants and young children.
As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signals potential future developments in therapeutic applications for probiotics in pediatric health. Companies involved in the development or manufacturing of probiotics, infant formula, or pediatric therapeutics should monitor the progress of this and similar patent applications as they may impact intellectual property landscapes and future product innovation in the sector.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
USES OF BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISM
Application US20260083785A1 Kind: A1 Mar 26, 2026
Inventors
Cheong Kwet Choy (William) KWONG CHUNG, Jean-Baptiste CAVIN, Claire Laurence Lucie Marie BOULANGE, Eleonora CIARLO
Abstract
The present invention relates to a Bifidobacterium longum transitional microorganism for use in preventing and/or reducing the risk of an infection in an infant or young child.
CPC Classifications
A61K 35/745 A61K 31/702 A61P 31/12 A61K 2035/115
Filing Date
2023-09-27
Application No.
19112879
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.